Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Can AbbVie Stock Keep Outpacing the S&P 500?

TheMotleyFool

0 0

Can AbbVie Stock Keep Outpacing the S&P 500?

Pharma stocks haven't been outstanding investments since the central bank began hiking rates in 2022. The core reason is that these companies depend on innovation to create value for shareholders -- an inherently risky endeavor.

AbbVie (NYSE: ABBV) has been one of the few exceptions to this trend. Despite losing exclusivity for its flagship immunology medication Humira in the U.S. in 2023, the drugmaker's shares are up by a healthy 30% over the past 12 months (total return, including dividends), even outpacing the red-hot S&P 500.